Safety under the regulatory spotlight — 90 documents in 90 days

6 documents in the last 30 days alone

This concentration of activity around safety may indicate a tightening cycle, particularly if the recent documents reflect more frequent scrutiny of adverse event reporting, signal detection, or risk mitigation expectations. Sponsors should consider that regulators may be prioritizing clearer evidence packages and faster post-market responsiveness, so companies with safety programs should watch for shifts in pharmacovigilance expectations, labeling sensitivity, and the degree of detail expected in benefit-risk narratives.